公开(公告)号：US20210038627A1

公开(公告)日：2021-02-11

申请号：US16804255

申请日：2020-02-28

Applicant: Lexicon Pharmaceuticals, Inc.

Inventor： Phillip BANKS ,  Sangeeta SAWHNEY

IPC: A61K31/7034 ,  A61K9/00

Abstract: The invention relates to the use of sotagliflozin to improve glycemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI)≥27 kg/m2.

公开(公告)号：US20220088048A1

公开(公告)日：2022-03-24

申请号：US17539548

申请日：2021-12-01

Applicant: Lexicon Pharmaceuticals, Inc.

Inventor： Phillip BANKS ,  Sangeeta SAWHNEY

IPC: A61K31/7034 ,  A61K9/00

Abstract: The invention relates to the use of sotagliflozin to improve glycemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI)≥27 kg/m2.

公开(公告)号：US20240226125A1

公开(公告)日：2024-07-11

申请号：US18613381

申请日：2024-03-22

Applicant: LEXICON PHARMACEUTICALS, INC.

Inventor： Phillip BANKS ,  Sangeeta SAWHNEY

IPC: A61K31/7034 ,  A61K9/00

CPC classification number: A61K31/7034 ,  A61K9/0053

Abstract: The invention relates to the use of sotagliflozin to improve glycemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥27 kg/m2.